• Follow
  • Follow
  • Follow
  • Home
  • About
  • Science
    • ALS
    • Parkinson’s Disease
  • Mitometin
    • Pipeline
  • News
  • Investors
  • Publications
  • Contact
  • Follow
  • Follow
  • Follow
  • Home
  • About
  • Science
    • ALS
    • Parkinson’s Disease
  • Mitometin
    • Pipeline
  • News
  • Investors
  • Publications
  • Contact

Post 5

by Web Developer | Oct 14, 2020 | Test

Post 4

by Web Developer | Oct 14, 2020 | Test

Post 3

Post 3

by Web Developer | Oct 14, 2020 | Test

Post 3

Post 2

by Web Developer | Oct 14, 2020 | Test

Post 3

Post 1

by Web Developer | Oct 14, 2020 | Test

Recent Posts

  • Poster Presentation at the 4th ALS Drug Discovery Summit
  • Matthias Wulf
  • 3rd ALS Drug Discovery Summit
  • New article in npj Parkinson’s Disease
  • 2N Pharma and our CSO mentioned in the Washington Post

Recent Comments

    2npharma

    2N Pharma is a small biotech company with a big vision: we want to cure ALS and other currently incurable neurodegenerative diseases.

    2N Pharma
    We are thrilled with today's publication of an art We are thrilled with today's publication of an article (in Danish) in Dansk Biotek and BusinessReview in which we discuss our innovative approach to treating #parkinsonsdisease and #ALS. Read full text here: https://lnkd.in/ejqXRqeR
    Today marks the third anniversary of 2N Pharma. We Today marks the third anniversary of 2N Pharma. We would like to thank our collaboration partners as well as our employees. #drugdevelopment #ALS #Parkinson #valentineday
    New article! 💙 (See link in bio) The results New article! 💙 (See link in bio) The results show that in mice with symptoms resembling Parkinson's disease, modulating cellular energy generation can restore both their motor and non-motor functions. Both toxicity-induced and genetic mouse models of Parkinson's disease were used to investigate this. Congratulations to Dr Michael Sloth Trabjerg MD, 2N Pharma Co-Founder, CSO and Aalborg University Associate Professor Dr John Dirk Vestergaard Nieland, and collaborators on the publication of their newest article in npj Parkinson’s Disease. #article #newarticle #parkinson #parkinsonsdisease #biotech #testing #cellularenergy #parkinsonsdiseaseawareness #brainhealth #braindisease #newmedicine #turnhopeintoreality #2npharma #mentalhealth #pharma #lifesciences #research #alsawareness #dementia #als #denmark #Aalborg #Nordjylland
    Do you want to learn more about the new medicines Do you want to learn more about the new medicines being developed by 2N Pharma, and the results we have achieved? Do you have any questions as a patient or relative about what you can do to improve your situation? 👉 Then save the date on April 26, 2023! Co-founder and CSO Dr. John Vestergaard Nieland, has, in collaboration with his research team, made breakthroughs in the development of new medicines to help improve the life expediency of Parkinson’s, Multiple Sclerosis and Alzheimer’s patients. In the lecture, John, will discuss how it all fits together. What we have tested for, and how we test it. Read more and sign up for the lecture at fuaalborg.dk - "Ny forskning om hjernens sygdomme - Parkinsons sygdom, Multiple Sklerose og Alzheimer" NB – this lecture is in Danish. #lecture #aalborguniversity #aalborguniversitet #brainhealth #braindisease #newmedicine #turnhopeintoreality #2npharma #mentalhealth #pharma #lifesciences #research #alsawareness #parkinsonsdisease #dementia #als #denmark #Aalborg #Nordjylland
    Load More... Follow on Instagram

    LinkedIn
    Twitter

    About
    Technology
    Pipeline
    News
    Investors
    Publications
    Contact

    Policies, Terms & Conditions
    Website Terms and Conditions
    Data Privacy Policy
    Cookie Policy
    GDPR Compliance
    2N Pharma ApS
    Novi Science Park, Niels Jernes Vej 10, 9220 Aalborg Ø, Denmark
    BioInnovation Institute, Ole Maaløes Vej 3, 2200 København N, Denmark
    CVR: 41169303 VAT: DK41169303 D-U-N-S: 306192737
    email: info@2npharma.com

    Twitter feed is not available at the moment.